The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
The company's new president and possible CEO is expected to have significant latitude to change things.
The trio will focus on using immune systems to attack cancer.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
AstraZeneca has been awarded $76 million in damages in a ruling over Apotex's sales of a generic version of Prilosec.
Impax Laboratories announced that it has reached an agreement with Purdue Pharma to settle patent litigation surrounding Impax's generic version of OxyContin.